 6. At least one accessible primary or metastatic tumor site that can be readily injected IT with poly-ICLC with or without ultrasound guidance. This lesion can be superficial cutaneous, subcutaneous or within a readily accessible lymph node and must measure at least 10 mm in longest dimension. 